Catalyst Event
Astrazeneca PLC (AZN) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
4/28/2026, 12:00:00 AM
Announced positive high-level results from the Phase III MIRANDA trial for tozorakimab, which showed a statistically significant reduction in exacerbations in patients with chronic obstructive pulmonary disease (COPD). Low importance as Phase III results for new indications typically see a 1-5% market reaction.
Korean Translation
만성 폐쇄성 폐질환(COPD) 환자에서 악화를 통계적으로 유의하게 감소시킨 토조라키맙(tozorakimab)의 3상 MIRANDA 임상시험에서 긍정적인 탑라인 결과를 발표함. 임상 결과 발표에 따른 시장 영향력이 1-5% 수준일 것으로 예상되어 낮은 중요도로 분류됨.
Related Recent Events
DICK'S Sporting Goods Inc (DKS) · Earnings Release
Q1 2026 earnings release is scheduled for 2026-05-27. Medium importance estimated as earnings releases for high-growth companies typically result in ≥5% price movement. Analysts forecast EPS of approximately $2.93 forecasted.
5/27/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
High importance estimated as earnings releases for major pharma often result in >10% price movement. Q1 2026 earnings release scheduled. Analysts forecast EPS of $0.87 and revenue of $11.35 billion forecasted.
5/6/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Eli Lilly reported Q1 2026 revenue of $19.8 billion (+56% YoY) and non-GAAP EPS of $8.55, beating estimates. The company raised its full-year 2026 revenue guidance to $82-$85 billion, driven by strong sales of Mounjaro and Zepbound. This significant growth and guidance raise is estimated to result in a >10% price impact.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
The U.S. FDA proposed removing tirzepatide, the active ingredient in Mounjaro and Zepbound, from the bulk drug substances list on 2026-04-30, restricting compounded versions. This regulatory protection of market share is estimated to result in a >10% price impact.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Reported Q1 2026 financial results, posting a GAAP Loss per Share of $1.72, which included a $3.62 per share charge from the acquisition of Cidara Therapeutics. Revenue grew 5% to $16.3 billion. The company raised its full-year 2026 guidance; high importance due to guidance raise and acquisition impact, market reaction expected.
4/30/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
High importance estimated as this regulatory change protects core revenue from competition, likely impacting price by >10%. The U.S. FDA proposed to exclude the active ingredients in key Novo Nordisk GLP-1 drugs from the bulk compounding list.
4/30/2026, 12:00:00 AM